Cambridge Investment Research Advisors
SCLN

Cambridge Investment Research Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-17,275
Closed -$151K – 1469
2014
Q4 		$151K Buy
17,275
+1,000
+6% +$8.09K ﹤0.01% 1261
2014
Q3 		$112K Buy
16,275
+100
+0.6% +$599 ﹤0.01% 1389
2014
Q2 		$85K Hold
16,175
– – ﹤0.01% 1294
2014
Q1 		$74K Hold
16,175
– – ﹤0.01% 1255
2013
Q4 		$82K Sell
16,175
-704
-4% -$3.39K ﹤0.01% 1189
2013
Q3 		$86K Hold
16,879
– – ﹤0.01% 1145
2013
Q2 		$84K Buy
+16,879
New +$80.3K ﹤0.01% 1065

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Cambridge Investment Research Advisors's SCLN Position: Q1 2015 in Review

Cambridge Investment Research Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 17,275 shares — an estimated $151K sold.

Cambridge Investment Research Advisors first reported a position in SCLN in Q2 2013 and held it in 7 quarters. The position peaked at $151K in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • Cambridge Investment Research Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 17,275 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $151K.
  • Cambridge Investment Research Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Cambridge Investment Research Advisors's Sciclone Pharmaceuticals Inc position peaked at $151K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2015, filed 4 May 2015.